Patents by Inventor Ryo Mizojiri

Ryo Mizojiri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORS
    Publication number: 20230117295
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 20, 2023
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Heterocyclic compound
    Patent number: 11584737
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: February 21, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji Ono, Masahiro Ito, Toshio Tanaka, Moriteru Asano, Takaharu Hirayama, Jun Fujimoto, Nobuki Sakauchi, Yasuhiro Hirata, Akinori Toita, Nao Morishita, Hironori Kokubo, Yasuhiro Imaeda, Hironobu Maezaki, Douglas Robert Cary, Ryo Mizojiri, Nobuo Cho, Hiroshi Banno, Hidekazu Tokuhara, Yasuyoshi Arikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20210363130
    Abstract: Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
    Type: Application
    Filed: March 28, 2019
    Publication date: November 25, 2021
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Koji ONO, Masahiro ITO, Toshio TANAKA, Moriteru ASANO, Takaharu HIRAYAMA, Jun FUJIMOTO, Nobuki SAKAUCHI, Yasuhiro HIRATA, Akinori TOITA, Nao MORISHITA, Hironori KOKUBO, Yasuhiro IMAEDA, Hironobu MAEZAKI, Douglas Robert CARY, Ryo MIZOJIRI, Nobuo CHO, Hiroshi BANNO, Hidekazu TOKUHARA, Yasuyoshi ARIKAWA
  • Bicyclic compound
    Patent number: 10301292
    Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 28, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Ryo Mizojiri, Hiroshi Banno, Moriteru Asano, Daisuke Tomita, Noriyuki Nii, Hironobu Maezaki, Michiko Tawada
  • Monocyclic compound
    Patent number: 10252997
    Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 9, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Moriteru Asano, Daisuke Tomita, Hiroshi Banno, Michiko Tawada, Noriyuki Nii, Krista E. Gipson, Hironobu Maezaki, Shuntarou Tsuchiya, Mayumi Imai, Yuichiro Amano
  • MONOCYCLIC COMPOUND
    Publication number: 20180079723
    Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.
    Type: Application
    Filed: March 30, 2016
    Publication date: March 22, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Moriteru ASANO, Daisuke TOMITA, Hiroshi BANNO, Michiko TAWADA, Noriyuki NII, Krista E. GIPSON, Hironobu MAEZAKI, Shuntaro TSUCHIYA, Mayumi IMAI, Yuichiro AMANO
  • BICYCLIC COMPOUND
    Publication number: 20180002322
    Abstract: Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 4, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Ryo Mizojiri, Hiroshi BANNO, Moriteru ASANO, Daisuke TOMITA, Noriyuki Nii, Hironobu MAEZAKI, Michiko TAWADA
  • Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
    Patent number: 9605000
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 28, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo Kasai, Masaki Ogino, Ryo Mizojiri, Takeshi Yamasaki, Hideki Hirose, Nobuyuki Takakura, Tohru Yamashita, Sachie Morimoto, Takashi Nakahata, Asato Kina
  • HETEROCYCLIC COMPOUND
    Publication number: 20160060273
    Abstract: Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.
    Type: Application
    Filed: March 13, 2014
    Publication date: March 3, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Shizuo KASAI, Masaki OGINO, Ryo MIZOJIRI, Takeshi YAMASAKI, Hideki HIROSE, Nobuyuki TAKAKURA, Tohru YAMASHITA, Sachie MORIMOTO, Takashi NAKAHATA, Asato KINA
  • Bicyclic compound
    Patent number: 9133129
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: September 15, 2015
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tohru Yamashita, Takuya Fujimoto, Ryo Mizojiri, Kazuko Yonemori, Hideki Hirose, Zenichi Ikeda, Ikuo Fujimori, Kyoko Toyofuku, Tsuneo Yasuma, Nobuyuki Matsunaga
  • BICYCLIC COMPOUND
    Publication number: 20140243310
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: October 23, 2012
    Publication date: August 28, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tohru Yamashita, Takuya Fujimoto, Ryo Mizojiri, Kazuko Yonemori, Hideki Hirose, Zenichi Ikeda, Ikuo Fujimori, Kyoko Toyofuku, Tsuneo Yasuma, Nobuyuki Matsunaga
  • Bicyclic compound
    Patent number: 8703758
    Abstract: The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 22, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tohru Yamashita, Makoto Kamata, Hideki Hirose, Masataka Murakami, Takuya Fujimoto, Zenichi Ikeda, Tsuneo Yasuma, Ikuo Fujimori, Ryo Mizojiri, Tomoya Yukawa
  • BICYCLIC COMPOUND
    Publication number: 20120142714
    Abstract: The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: November 29, 2011
    Publication date: June 7, 2012
    Inventors: TSUNEO YASUMA, MAKOTO KAMATA, TOHRU YAMASHITA, HIDEKI HIROSE, MASATAKA MURAKAMI, ASATO KINA, KAZUKO YONEMORI, RYO MIZOJIRI, IKUO FUJIMORI, TAKUYA FUJIMOTO, ZENICHI IKEDA
  • 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR
    Publication number: 20120020920
    Abstract: The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
    Type: Application
    Filed: February 24, 2011
    Publication date: January 26, 2012
    Applicant: Japan Tobacco Inc.
    Inventors: Ryo Mizojiri, Shintaro Hirashima, Takahiro Oka, Kenta Aoki, Satoru Noji, Izuru Ando, Toshihiro Sato, Yasushi Niwa
  • BICYCLIC COMPOUND
    Publication number: 20110263562
    Abstract: The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.
    Type: Application
    Filed: April 26, 2011
    Publication date: October 27, 2011
    Inventors: Tohru Yamashita, Makoto Kamata, Hideki Hirose, Masataka Murakami, Takuya Fujimoto, Zenichi Ikeda, Tsuneo Yasuma, Ikuo Fujimori, Ryo Mizojiri, Tomoya Yukawa
  • Aminopyridine compounds having Syk inhibitory activity
    Patent number: 7803801
    Abstract: The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X1, X2, X3, Z, Y1, Y2 represent a carbon atom or a nitrogen atom, R, R1, R5, R6 represent a hydrogen atom, an alkyl group, etc., and R7 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, —CpH2(p-1)(Ra1)(Ra2)—O—Ra3, —C(?O)—Rd1, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, —N(Rh1)(Rh2), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: September 28, 2010
    Assignee: Japan Tobacco, Inc.
    Inventors: Yoshitoshi Kodama, Satoru Noji, Katsuaki Imamura, Ryo Mizojiri, Kenta Aoki, Hideo Takagi, Yuichi Naka, Goro Ito, Kiyotaka Shinoda, Akihito Fujiwara, Kazunori Kurihara, Masaru Tanaka
  • Thienopyrrole compound and use thereof as HCV polymerase inhibitor
    Patent number: 7659263
    Abstract: The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: February 9, 2010
    Assignee: Japan Tobacco Inc.
    Inventors: Ryo Mizojiri, Takahiro Oka, Kenta Aoki, Satoru Noji, Yoko Matsumoto, Toshihiro Sato, Izuru Ando, Yasushi Niwa
  • 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor
    Publication number: 20090036444
    Abstract: The present invention relates to a fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
    Type: Application
    Filed: May 18, 2006
    Publication date: February 5, 2009
    Applicant: Japan Tobacco Inc.
    Inventors: Ryo Mizojiri, Shintaro Hirashima, Takahiro Oka, Kenta Aoki, Satoru Noji, Izuru Ando, Toshihiro Sato, Yasushi Niwa
  • Novel aminopyridine compounds having Syk inhibitory activity
    Publication number: 20060205731
    Abstract: The present invention relates to an aminopyridine compound represented by the following general formula (I) or a salt thereof and an Syk inhibitor containing the compound or a salt thereof as an active ingredient. Here, X1, X2, X3, Z, Y1, Y2 represent a carbon atom or a nitrogen atom, R, R1, R5, R6 represent a hydrogen atom, an alkyl group, etc., and R7 represents a hydrogen atom, a halogen atom, a nitro group, a cyano group, —CpH2(p-1)(Ra1)(Ra2)—O—Ra3, —C(?O)—Rd1, a 5- or 6-membered saturated heterocyclic group, an aromatic heterocyclic group, —N(Rh1)(Rh2), etc. The aminopyridine compound of the present invention has not only high Syk inhibitory activity but also properties to selectively inhibit Syk.
    Type: Application
    Filed: February 28, 2006
    Publication date: September 14, 2006
    Applicant: JAPAN TOBACCO INC.
    Inventors: Yoshitoshi Kodama, Satoru Noji, Katsuaki Imamura, Ryo Mizojiri, Kenta Aoki, Hideo Takagi, Yuichi Naka, Goro Ito, Kiyotaka Shinoda, Akihito Fujiwara, Kazunori Kurihara, Masaru Tanaka
  • Thienopyrrole compound and use thereof as HCV polymerase inhibitor
    Publication number: 20060167246
    Abstract: The present invention relates to a thienopyrrole compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound as an active ingredient. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.
    Type: Application
    Filed: November 10, 2005
    Publication date: July 27, 2006
    Applicant: Japan Tobacco Inc.
    Inventors: Ryo Mizojiri, Takahiro Oka, Kenta Aoki, Satoru Noji, Yoko Matsumoto, Toshihiro Sato, Izuru Ando, Yasushi Niwa